weiss jemand was mit novoste los ist??? - 500 Beiträge pro Seite
eröffnet am 20.12.01 21:05:51 von
neuester Beitrag 11.01.02 13:37:32 von
neuester Beitrag 11.01.02 13:37:32 von
Beiträge: 5
ID: 525.226
ID: 525.226
Aufrufe heute: 0
Gesamt: 171
Gesamt: 171
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 7310 | |
| vor 24 Minuten | 3366 | |
| vor 36 Minuten | 3357 | |
| vor 51 Minuten | 1441 | |
| vor 24 Minuten | 1435 | |
| vor 38 Minuten | 1331 | |
| vor 33 Minuten | 1071 | |
| vor 1 Stunde | 1063 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 2. | 6,3420 | -1,15 | 102 | |||
| 2. | 1. | 18.677,25 | -0,34 | 73 | |||
| 3. | 4. | 9,9100 | -3,97 | 64 | |||
| 4. | 3. | 169,26 | -1,52 | 60 | |||
| 5. | 21. | 9,5350 | +0,05 | 52 | |||
| 6. | 9. | 0,1523 | -2,68 | 31 | |||
| 7. | 23. | 0,0200 | +31,58 | 30 | |||
| 8. | 8. | 2.410,42 | -0,43 | 30 |
Feedback
minus 30% heute! finde aber keine nachricht!!
Der CEO ist zurückgetreten:
Novoste stock tumbles on CEO departure
(UPDATE: Adds analyst comments, updates stock price in paragraphs 1-4)
NEW YORK, Dec 20 (Reuters) - Medical device firm Novoste Corp. (NasdaqNM:NOVT - news) on Thursday said President and Chief Executive William Hawkins is leaving the firm to join Medtronic Inc. (NYSE:MDT - news), sending shares down 26 percent.
ADVERTISEMENT
The stock tumbled $3.14 to $8.77 in early trade on the Nasdaq, making it the largest percentage loser -- a drop some industry analysts called an overreaction. The stock fell as low as $7.95.
``I don`t think the sell-off is warranted,`` said Kurt Kruger, an analyst with Banc of America Securities.
``His contributions were significant, but at the same time, the market should be careful to read anything into his departure. It was entirely based on the attractiveness to be one of the top bananas at the premier medical device firm on the planet.``
Hawkins will become senior vice president at Medtronic, the world`s largest medical device firms, and president of its vascular division.
Norcross, Georgia-based Novoste, which has developed the Beta-Cath system that uses radiation to help keep arteries open following a coronary angioplasty and stent implantation, said its board is currently reviewing CEO candidates. It expects to name a successor during the next few months.
In the interim, company co-founder and Chairman Thomas Weldon, will step back into the role of CEO, a position he held prior to Hawkins` appointment four year ago.
``In the near term, we will continue to focus on growing our vascular brachytherapy business,`` Weldon said in a statement.
``Over the longer term, we plan to leverage our core technology into new markets and aggressively pursue internal and external strategic growth opportunities that exploit our brand and distribution capabilities. Our new CEO will drive this strategy,`` he said.
Novoste stock tumbles on CEO departure
(UPDATE: Adds analyst comments, updates stock price in paragraphs 1-4)
NEW YORK, Dec 20 (Reuters) - Medical device firm Novoste Corp. (NasdaqNM:NOVT - news) on Thursday said President and Chief Executive William Hawkins is leaving the firm to join Medtronic Inc. (NYSE:MDT - news), sending shares down 26 percent.
ADVERTISEMENT
The stock tumbled $3.14 to $8.77 in early trade on the Nasdaq, making it the largest percentage loser -- a drop some industry analysts called an overreaction. The stock fell as low as $7.95.
``I don`t think the sell-off is warranted,`` said Kurt Kruger, an analyst with Banc of America Securities.
``His contributions were significant, but at the same time, the market should be careful to read anything into his departure. It was entirely based on the attractiveness to be one of the top bananas at the premier medical device firm on the planet.``
Hawkins will become senior vice president at Medtronic, the world`s largest medical device firms, and president of its vascular division.
Norcross, Georgia-based Novoste, which has developed the Beta-Cath system that uses radiation to help keep arteries open following a coronary angioplasty and stent implantation, said its board is currently reviewing CEO candidates. It expects to name a successor during the next few months.
In the interim, company co-founder and Chairman Thomas Weldon, will step back into the role of CEO, a position he held prior to Hawkins` appointment four year ago.
``In the near term, we will continue to focus on growing our vascular brachytherapy business,`` Weldon said in a statement.
``Over the longer term, we plan to leverage our core technology into new markets and aggressively pursue internal and external strategic growth opportunities that exploit our brand and distribution capabilities. Our new CEO will drive this strategy,`` he said.
Die kommen wieder. Zeit zum NACHKAUFEN!!!!
Gestern zu Handelende wieder mächtig nach oben gegangen.
Habs gesagt, war einfach übertrieben der einbruch vor 2 Wochen
Habs gesagt, war einfach übertrieben der einbruch vor 2 Wochen
Hallo!
Meiner Meinung nach ist diese Aktie völlig unterbewertet (letztes Quartal positiv, steigende Umsätze, erwartetes Ergebnis 2002: 1,23, also KGV von ca. 7 und erfolgreiches Produkt), dazu kommt noch reichlich Platz für Spekulationen. Wer sagt, dass Medtronic nicht Interesse an einer Übernahme hätte, den alten CEO haben sie ja schon an Board geholt.
Also, Conclusio:
Die Aktie hat enormes Steigerungspotential.
Meiner Meinung nach ist diese Aktie völlig unterbewertet (letztes Quartal positiv, steigende Umsätze, erwartetes Ergebnis 2002: 1,23, also KGV von ca. 7 und erfolgreiches Produkt), dazu kommt noch reichlich Platz für Spekulationen. Wer sagt, dass Medtronic nicht Interesse an einer Übernahme hätte, den alten CEO haben sie ja schon an Board geholt.
Also, Conclusio:
Die Aktie hat enormes Steigerungspotential.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 107 | ||
| 69 | ||
| 59 | ||
| 53 | ||
| 52 | ||
| 32 | ||
| 29 | ||
| 28 | ||
| 27 | ||
| 26 |
| Wertpapier | Beiträge | |
|---|---|---|
| 25 | ||
| 24 | ||
| 24 | ||
| 22 | ||
| 20 | ||
| 20 | ||
| 18 | ||
| 18 | ||
| 17 | ||
| 17 |
